Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

2.9K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
2.9K
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

4.1K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.1K
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

38
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
38
Study Designs in Epidemiology01:20

Study Designs in Epidemiology

159
Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
159
Crossover Experiments01:16

Crossover Experiments

2.7K
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
2.7K
Odds Ratio01:09

Odds Ratio

94
The odds ratio (OR) is a statistical measure used extensively in epidemiology and research to quantify the strength of association between exposure and outcome across different groups. Unlike relative risk, which compares the probabilities of an event occurring, the odds ratio compares the odds of an event occurring in the exposed group to the odds of it occurring in the unexposed group. The odds, in this context, are calculated as the probability of the event happening divided by the...
94

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimizing intravenous solid tumour treatment through active targeting approaches and polymeric micelles engineering: A meta-analysis in mouse models.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Model robust designs for dose-response models.

Biometrics·2025
Same author

Cleaning validation in pharmaceutical quality control laboratories: a structured protocol for contamination risk mitigation.

Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences·2025
Same author

Optimum designs for clinical trials in personalized medicine when response variance depends on treatment.

Journal of biopharmaceutical statistics·2024
Same author

Modeling the Batch Sedimentation of Calcium Carbonate Particles in Laboratory Experiments-A Systematic Approach.

Materials (Basel, Switzerland)·2023
Same author

Randomizing a clinical trial in neuro-degenerative disease.

Contemporary clinical trials communications·2023

Related Experiment Video

Updated: May 26, 2025

Characterization of Complex Systems Using the Design of Experiments Approach: Transient Protein Expression in Tobacco as a Case Study
20:24

Characterization of Complex Systems Using the Design of Experiments Approach: Transient Protein Expression in Tobacco as a Case Study

Published on: January 31, 2014

16.4K

Optimal designs for efficacy-toxicity response in dose finding studies using the bivariate probit model.

Belmiro P M Duarte1, Anthony C Atkinson2

  • 1Polytechnic Institute of Coimbra, ISEC, Department of Chemical & Biological Engineering, Rua Pedro Nunes, 3030-199 Coimbra, Portugal; University of Coimbra, INESC-Coimbra, Rua Sílvio Lima - Pólo II, 3030-790 Coimbra, Portugal; University of Coimbra, CERES, Department of Chemical Engineering, Rua Sílvio Lima - Pólo II, 3030-790 Coimbra, Portugal.

Computers in Biology and Medicine
|February 23, 2025
PubMed
Summary

This study introduces optimal experimental designs for extended Phase I clinical trials, focusing on both drug efficacy and toxicity. The methods utilize a bivariate probit model and Semidefinite Programming for correlated responses.

Keywords:
Dose–response modelsEfficacy-ToxicityK–optimalityOptimal design of experimentsProbit modelSemidefinite Programming

More Related Videos

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

4.3K
Optimization of Processing of Tiebangchui with Highland Barley Wine Based on the Box-Behnken Design Combined with the Entropy Method
09:12

Optimization of Processing of Tiebangchui with Highland Barley Wine Based on the Box-Behnken Design Combined with the Entropy Method

Published on: May 19, 2023

569

Related Experiment Videos

Last Updated: May 26, 2025

Characterization of Complex Systems Using the Design of Experiments Approach: Transient Protein Expression in Tobacco as a Case Study
20:24

Characterization of Complex Systems Using the Design of Experiments Approach: Transient Protein Expression in Tobacco as a Case Study

Published on: January 31, 2014

16.4K
A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

4.3K
Optimization of Processing of Tiebangchui with Highland Barley Wine Based on the Box-Behnken Design Combined with the Entropy Method
09:12

Optimization of Processing of Tiebangchui with Highland Barley Wine Based on the Box-Behnken Design Combined with the Entropy Method

Published on: May 19, 2023

569

Area of Science:

  • Clinical trial design
  • Biostatistics
  • Experimental design

Background:

  • Phase I clinical trials traditionally prioritize drug safety and maximum tolerated dose determination.
  • Efficacy assessment is often a secondary objective in Phase I studies.
  • Extended Phase I trials offer opportunities to simultaneously evaluate efficacy and toxicity.

Purpose of the Study:

  • To develop optimal experimental designs for extended Phase I clinical trials.
  • To address situations where both drug efficacy and toxicity are measured and correlated.
  • To investigate the impact of correlation, prior knowledge, constraints, and drug combinations on design optimality.

Main Methods:

  • Utilized a bivariate probit model to represent correlated efficacy and toxicity responses.
  • Employed Semidefinite Programming for constructing locally optimal experimental designs.
  • Considered various scenarios including correlation strength, known vs. unknown correlation, design constraints, and single vs. combined drugs.
  • Applied D-, A-, E-, and K-optimality criteria.

Main Results:

  • Developed systematic numerical approaches for optimal experimental design in extended Phase I trials.
  • Demonstrated the optimality of the proposed designs using equivalence theorems.
  • Derived an equivalence theorem specifically for the K-optimality criterion.
  • Showcased the adaptability of the methodology across diverse design considerations.

Conclusions:

  • The proposed Semidefinite Programming-based methodology provides a robust framework for optimizing experimental designs in extended Phase I clinical trials.
  • The findings offer practical insights for balancing efficacy and safety evaluations in early-phase drug development.
  • The developed designs are adaptable to various correlation structures, constraints, and drug combinations, enhancing trial efficiency.